MIST Milestone Pharmaceuticals

Milestone® Pharmaceuticals to Present at Upcoming Conferences

Milestone® Pharmaceuticals to Present at Upcoming Conferences

MONTREAL and CHARLOTTE, N.C., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced President and CEO, Joe Oliveto, will participate in one-on-one meetings at the Wells Fargo Healthcare Conference, to take place September 3 - 5, 2025, in Boston and will provide a corporate update at the H.C. Wainwright 27th Annual Global Investment Conference, to take place September 8 – 10, 2025, in New York.

A webcast of the H.C. Wainwright presentation will be available on September 9 at 12:00 PM EDT. The webcast will be available to watch and a replay will be available for approximately 90-days following the presentation on the News & Events section of Milestone's website

If you are interested in meeting with the Milestone team during the conference, please reach out to your Wells Fargo or H.C. Wainwright representative.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company developing and commercializing innovative cardiovascular medicines to benefit people living with certain heart conditions. Milestone recently submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil for treatment of an abnormal heart rhythm, paroxysmal supraventricular tachycardia or PSVT.

Contact

Investor Relations

Kevin Gardner,



EN
19/08/2025

Underlying

MISTMilestone Pharmaceuticals

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Milestone Pharmaceuticals

 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel a...

Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer New appointment strengthens executive leadership commensurate with launch of CARDAMYST™ (etripamil) nasal spray MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval’s appointment comes as , the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular ...

February 10, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listi...

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) MONTREAL and CHARLOTTE, N.C., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST) (the “Company” or “Milestone”), today announced that the Company granted equity awards, in the form of a total of 419,000 options (the “Options”) to purchase the Company’s common shares, pursuant to the Company’s 2021 Inducement Plan (the “Plan”), previously approved by the Company’s Compensation Committee and the Board of Directors, as a material inducement to the hiring of two new employees....

February 3, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (e...

Milestone Pharmaceuticals Announces U.S. Availability of CARDAMYST™ (etripamil) Nasal Spray, the First and Only FDA-Approved Self-Administered Treatment for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) CARDAMYST is now conveniently available to patients through retail pharmaciesNational sales force hired with promotional launch in mid-FebruaryExpected $25 copay cap for eligible commercially insured patientsLaunch supported by comprehensive patient assistance program offering benefits verification and reimbursement support MONTREAL and CHARLOTTE, N.C., Jan. 26, 2026 (GLOB...

January 26, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorizat...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency  European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective self-administered treatment option for PSVT outside of the healthcare setting MONTREAL and CHARLOTTE, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medici...

January 6, 2026 1 EN
 PRESS RELEASE
Free
MIST Milestone Pharm...

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and...

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT) First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTT...

December 13, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch